Peptide News Digest

#Zupreme-1

2 stories

Clinical Trials · View digest

Roche Petrelintide ZUPREME-1 at ADA: Amylin Analog Targets the 30-40% of Patients Who Quit GLP-1s for GI Tolerability

Roche presented ZUPREME-1 Phase 2 data for petrelintide, the once-weekly long-acting amylin analog licensed from Zealand Pharma, at the Monday June 8 investor event. The pitch hinges on tolerability: published topline showed up to 10.7% weight loss at 42 weeks versus 1.7% placebo, with discontinuation 4.8% vs 4.9% placebo and no vomiting at the maximally effective dose. Medical Daily framed the readout as a non-incretin option for the estimated 30-40% of patients who quit GLP-1s for GI side effects. Petrelintide advances to Phase 3 alongside enicepatide.

Clinical Trials · View digest

Roche and Zealand's Petrelintide Heads to ADA 2026 as a Late-Breaker: 10.7% Weight Loss and No Vomiting at the Top Dose in Phase 2 ZUPREME-1

Roche will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide as an ADA 2026 late-breaker, with a June 8 investor event. In 493 adults with overweight or obesity (mean BMI 37), once-weekly petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% on placebo, with treatment discontinuation of 4.8% versus 4.9% on placebo and no vomiting or GI-related discontinuations at the maximally effective dose. That tolerability is the amylin class's central pitch against the incretins.